Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan-Reference-Cited by-同舟云学术

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan

Published:2022-06-09 Issue:7 Volume:24 Page:804-813
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J of Clinical Hypertension

Author:

Danaietash Parisa¹,Verweij Pierre¹,Wang Ji‐Guang²^ORCID,Dresser George³,Kantola Ilkka⁴,Lawrence Mary Katherine⁵,Narkiewicz Krzysztof⁶,Schlaich Markus⁷^ORCID,Bellet Marc¹^ORCID,

Affiliation:

1. Idorsia Pharmaceuticals Ltd. Allschwil Basel‐Landschaft Switzerland

2. Rui Jin Hospital Shanghai Jiaotong University School of Medicine Shanghai China

3. London Health Sciences Centre ‐ Victoria Hospital London Ontario Canada

4. Division of Medicine Turku University Central Hospital Turku Finland

5. Carteret Medical Group Morehead City North Carolina USA

6. Medical University of Gdańsk Gdańsk Poland

7. Dobney Hypertension Centre, Departments of Cardiology and Nephrology Royal Perth Hospital Unit ‐ University of Western Australia Perth Western Australia Australia

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.14517

Reference33 articles.

1. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys

2. Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups

3. 2018 ESC/ESH Guidelines for the management of arterial hypertension

4. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

5. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A New Class of Drugs Approved in the United States for Hypertension: Endothelin Antagonists;The American Journal of Medicine;2024-09

2. Hypertension and Heart Failure: From Pathophysiology to Treatment;International Journal of Molecular Sciences;2024-06-17

3. Aprocitentan: First Approval;Drugs;2024-06-04

4. Aprocitentan: a novel option for treatment of resistant arterial hypertension;Polish Archives of Internal Medicine;2024-05-28

5. Resistant Hypertension: Disease Burden and Emerging Treatment Options;Current Hypertension Reports;2024-02-16